RxDoctor Payments Data

Tanya Doctorian, MD

Advanced Heart Failure and Transplant Cardiology · Loma Linda, CANPI 1275917940

Payments from drug & device makers

$465in general payments, 2019–2025

Across 23 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$92
  • Novo Nordisk$90
  • Abbott$52
  • Scpharmaceuticals Inc.$49
  • Lexicon Pharmaceuticals, Inc.$29
  • Boehringer Ingelheim$26
  • plus $127 from 7 others

What the payments were for

  • Food & beverage$465100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$465 in reported general payments places this provider in the 5th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$102,540
Medicare patients
399
Services billed
1,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan183$233,028
JardianceEmpagliflozin82$93,274
FarxigaDapagliflozin Propanediol89$74,057
EliquisApixaban51$46,366
XareltoRivaroxaban11$9,286
Tacrolimus29$1,702
Metoprolol Succinate178$1,700
Mycophenolate Mofetil14$1,618
Bumetanide31$1,334
Atorvastatin Calcium190$1,271
Furosemide141$1,008
Amiodarone Hcl15$876
Carvedilol119$802
Losartan Potassium83$595
Spironolactone77$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$16$233,028183 claims
Boehringer IngelheimJardiance$26$93,27482 claims
AstraZenecaFarxiga$15$74,05789 claims
PfizerEliquis$92$46,36651 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →